Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.92 -0.19 (-0.23%)
Official Closing Price Updated: 7:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,709,061
Open 84.41
Bid (Size) 83.62 (3)
Ask (Size) 83.99 (1)
Prev. Close 84.11
Today's Range 83.60 - 85.50
52wk Range 73.31 - 111.20
Shares Outstanding 2,531,374,696
Dividend Yield 3.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing. 
Via Benzinga
2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off
The Dow Jones (^DJI) is home to corporate giants, but size alone doesn’t guarantee success. A few of these companies are struggling with weak fundamentals, paradigm shifts, or poor execution. 
Via StockStory
Topics Artificial Intelligence Stocks

Performance

YTD
-15.4%
-15.4%
1 Month
+3.5%
+3.5%
3 Month
+2.9%
+2.9%
6 Month
+7.6%
+7.6%
1 Year
-24.0%
-24.0%

More News

Read More
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
Via Benzinga
Merck & Co. Inc. (NYSE:MRK) Demonstrates Dividend Strength and Sustainability
Via Chartmill
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Via Benzinga
Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Via Benzinga
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
Via The Motley Fool
Topics Intellectual Property
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Via MarketMinute
Topics Artificial Intelligence
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
Via StockStory
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Via MarketBeat
Topics Artificial Intelligence
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
Via MarketMinute
Topics Economy Government Stocks
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Via The Motley Fool
Topics ETFs Government World Trade
Inflation's Shadow Lengthens: September CPI Ignites Fed Caution Amidst Government Shutdown
Via MarketMinute
Topics Bonds Economy World Trade
Global Markets Diverge: Asian Shares Stumble Amid US-China Trade Tensions, While Wall Street Futures Rebound
Via MarketMinute
Topics Artificial Intelligence Economy Government
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments
Via Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
Via MarketMinute
Topics Artificial Intelligence Economy Government
Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector
Via MarketMinute
Topics Economy
Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market
Via MarketMinute
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
Via MarketMinute
Topics Economy Intellectual Property Retirement
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
5 Healthcare Plays Powering the Sector’s Big Comeback
Via MarketBeat

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 83.92
When was Merck & Co last traded?
The last trade of Merck & Co was at 10/16/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 212.43B
How many shares of Merck & Co are outstanding?
Merck & Co has 212B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.